^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

Chr t(8;21)(q22;q22)

3ms
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia. (PubMed, Exp Hematol Oncol)
Our work reveals a therapeutic potential of targeting AML1-ETO/FTO/IGFBP2 minicircuitry in the treatment for t(8;21) patients with resistance to Ara-C.
Journal
|
IGFBP2 (Insulin-like growth factor binding protein 2) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
Chr t(8;21)(q22;q22) • FTO expression
|
cytarabine
6ms
Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation. (PubMed, Leukemia)
We also observed dysregulation of key hematopoietic transcription factor target gene networks, blocking cellular differentiation. Finally, we identified Sox4 activation as a potential contributor to stem cell self-renewal during the pre-leukemic stage.
Preclinical • Journal
|
SOX4 (SRY-Box Transcription Factor 4)
|
Chr t(8;21)(q22;q22)
over1year
Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study. (PubMed, J Clin Pathol)
MS diagnosis is usually challenging; an expanded immunohistochemical panel should be used for an accurate diagnosis. Although MS generally has a poor prognosis, increasing age appears to be associated with a worse outcome.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD68 (CD68 Molecule)
|
Chr t(8;21)(q22;q22)
over1year
Acute myeloid leukemia patients with variant or unusual translocations involving chromosomes 8 and 21 - A comprehensive cytogenetic profiling of three cases with review of literature. (PubMed, J Cancer Res Ther)
AML with t(8;21)(q22;q22);RUNX1-RUNX1T1 forms a distinct WHO subcategory and hence the identification of variants or unusual translocations associated with t(8;21) deserves more attention. Contribution to the variant/ unusual t(8;21) database will further refine the risk stratification and may help to significantly advance the current treatment regimen.
Review • Journal
|
RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
|
Chr t(8;21)(q22;q22)
almost2years
CHROMOSOMAL ABNORMALITIES DURING THE CLINICAL COURSE OF ADULT ACUTE MYELOID LEUKEMIA (EHA 2022)
Taking into consideration the identified cytogenetic abnormalities AML patients were classified by risk groups . Presence of the additional/secondary chromosomal aberrations in leukemic cells or new cells clones with multiple structural and numerical changes at AML relapse is the one sign of clonal evolution and progression of disease .
Clinical
|
ABL1 (ABL proto-oncogene 1) • CBFB (Core-Binding Factor Subunit Beta 2)
|
BCR-ABL1 fusion • Chr del(5q) • Chr del(7q) • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion • Chr t(8;21)(q22;q22)
almost3years
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). (PubMed, Blood Adv)
In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21).
Retrospective data • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
KIT mutation • Chr t(8;21)(q22;q22)
almost3years
Complex rearrangement in acute myeloid leukemia M2 with RUNX1/RUNX1T1 fusion involving chromosomes 8, 17 and 21. (PubMed, Mol Cytogenet)
The present case highlights importance of complex rearrangements rarely encountered in AML, suggesting that all involved regions harbor critical candidate genes regulating the pathogenesis of AML, leading to novel as well as well-known leukemia associated chromosomal aberrations.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
|
FLT3-ITD mutation • RUNX1-RUNX1T1 fusion • Chr t(8;21)(q22;q22)
3years
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3'UTR. (PubMed, Exp Hematol Oncol)
AML1-ETO is post-transcriptionally regulated by let-7b, which contributes to the leukemic phenotype of t(8;21) AML and may be important for t(8;21) leukemogenesis and maintenance.
Journal
|
RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
|
Chr t(8;21)(q22;q22)